drugset / Trial / NCT07544628

A Phase 1 Study of Navlimetostat Tablet Formulations

NCT07544628

Phase 1 Recruiting 64 enrolled Bristol-Myers Squibb
RandomizedCrossoverOpen-labelTreatment

Summary

This study aims to compare the PK of Navlimetostat after administration of a wet-granulation tablet versus the dry-granulation tablet formulation in healthy adult female

Timeline

Start
2026-04-27
Primary completion
2026-08-31
Completion
2026-10-15

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-986504 Unknown

Indications

No indication recorded.